Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, aTyr Pharma's Enterprise Value is $-6.86 Mil.
aTyr Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-59.08 Mil. Therefore, aTyr Pharma's EV-to-OCF for today is 0.12.
The historical rank and industry rank for aTyr Pharma's EV-to-OCF or its related term are showing as below:
ATYR'
s EV-to-OCF Range Over the Past 10 Years
Min: -6.37 Med: -0.22 Max: 2.5
Current: 0.12
During the past 13 years, the highest EV-to-OCF of aTyr Pharma was 2.50. The lowest was -6.37. And the median was -0.22.
ATYR's EV-to-OCF is ranked worse than 72.62% of 1410
companies
in the Biotechnology industry
Industry Median: -3.345
vs ATYR: 0.12
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
aTyr Pharma's PE Ratio (TTM) for today is calculated as:
aTyr Pharma's share price for today is $0.491.
aTyr Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.730.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
aTyr Pharma EV-to-OCF Related Terms
aTyr Pharma EV-to-OCF Historical Data
* Premium members only.
The historical data trend for aTyr Pharma's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, aTyr Pharma's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
aTyr Pharma EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, aTyr Pharma's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where aTyr Pharma's EV-to-OCF falls into.
aTyr Pharma's current Enterprise Value is $-6.86 Mil.
aTyr Pharma's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-59.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
aTyr Pharma (ATYR) has a EV-to-OCF of 0.12 as of Aug. 01, 2026. According to the industry distribution chart, aTyr Pharma ranks #1024 out of 1410 companies in the Biotechnology industry, placing it in the top 72.6%.
Is aTyr Pharma's EV-to-OCF too high?
aTyr Pharma's current EV-to-OCF is 0.12. Based on the distribution chart, aTyr Pharma ranks #1024 out of 1410 companies in the Biotechnology industry, which is below the industry midpoint. Overall, aTyr Pharma has a GF Score™ of 14/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does aTyr Pharma's EV-to-OCF compare to IBO and BYSI?
According to the Biotechnology industry distribution chart, aTyr Pharma ranks #1024 out of 1410 companies for EV-to-OCF. This places aTyr Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. aTyr Pharma's current EV-to-OCF is 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is aTyr Pharma stock overvalued right now?
Based on GuruFocus' analysis, aTyr Pharma (ATYR) is currently considered Fairly Valued. The stock's GF Value™ is $0.45, compared to a current price of $0.49 — trading 9.1% above its estimated fair value. The current EV-to-OCF is 0.12. aTyr Pharma's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For aTyr Pharma (ATYR), the current EV-to-OCF is 0.12 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is aTyr Pharma (ATYR) Overvalued in 2026?
Based on GuruFocus' analysis, aTyr Pharma stock appears to be overvalued.
The current stock price of $0.49 is trading 9.1% above its estimated GF Value™ of $0.45.
GuruFocus considers aTyr Pharma to be Fairly Valued.
Key valuation signals for ATYR:
EV-to-OCF: 0.12
GF Value™: $0.45 vs. price of $0.49 (9.1% above fair value)
No single metric tells the full story. See the ATYR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
14GF Score
Get the complete analysis for ATYR
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATYR has been successfully added to your 
